Medtronic defiant in spite of SCOTUS TAVI patent appeal rejection
This article was originally published in Clinica
Executive Summary
Medtronic remains confident about its future in the US transcatheter aortic valve implantation (TAVI) market in spite of the recent knockback from the US Supreme Court, which rejected the company’s appeal to overturn a 2010 ruling that favored arch rival Edwards Lifesciences.